Community monitoring can track environmental phenomena, resource use, and natural resource management processes of concern to community members. It can also contribute to planning and decision-making and empower community members in resource management. While community monitoring that addresses the environmental crisis is growing, it also gathers data on other global challenges: climate change, social welfare, and health. Some environmental community monitoring programs are challenged by limited collective action and community participation, insufficient state responsiveness to data and proposals, and lack of sustainability over time. Additionally, community members monitoring the environment are increasingly harassed and sometimes killed. Community monitoring is more effective with improved data collection, improved data management and sharing, and stronger efforts to meet community information needs, enable conflict resolution, and strengthen self-determination. Other promising areas for development are further incorporating governance issues, embracing integrated approaches at the community level, and establishing stronger links to national and global frameworks. Expected final online publication date for the Annual Review of Environment and Resources, Volume 47 is October 2022. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.

In order to define an in vitro integrated testing strategy (ITS) for estrogenicity, a set of 23 reference compounds representing diverse chemical classes were tested in a series of in vitro assays including proliferation and reporter gene assays. Outcomes of these assays were combined with published results for estrogen receptor (ER) binding assays and the OECD validated BG1Luc ER transcriptional activation (TA) assay and compared with the outcomes of the in vivo uterotrophic assay to investigate which assays most accurately predict the in vivo uterotrophic effect and to identify discrepancies between the in vitro assays and the in vivo uterotrophic assay. All in vitro assays used revealed a reasonable to good correlation (R(2)  = 0.62-0.87) with the in vivo uterotrophic assay but the combination of the yeast estrogen bioassay with the U2OS ERα-CALUX assay seems most promising for an ITS for in vitro estrogenicity testing. The main outliers identified when correlating data from the different in vitro assays and the in vivo uterotrophic assay were 4-hydroxytamoxifen, testosterone and to a lesser extent apigenin, tamoxifen and kepone. Based on the modes of action possibly underlying these discrepancies it becomes evident that to further improve the ITS and ultimately replace animal testing for (anti-)estrogenic effects, the selected bioassays have to be combined with other types of in vitro assays, including for instance in vitro models for digestion, bioavailability and metabolism of the compounds under investigation.

No abstract

No abstract